Integrated Biopharma Solutions: From Bench To Commercial

If you're evaluating contract development and manufacturing partners for your biologics program, the range of modalities a CDMO can credibly handle matters as much as its regulatory track record. Eurofins CDMO brings over 20 years of full-service experience covering drug substance and drug product analytical and process development, aseptic fill scale-up, stability and toxicology batches, and clinical Phase 1 and 2 manufacturing, all under one roof in Mississauga, Ontario.

The modality breadth here is notable. Monoclonal antibodies (mAbs), bispecific antibodies (bsAbs), antibody-drug conjugates (ADCs), Fc fusion proteins, virus-like particles (VLPs), glycoproteins, cytokines, biosimilars, and protein vaccines are all within scope. Intensified biomanufacturing is a specific area of focus, which matters if your process economics or timeline are under pressure.

Facility-wise, a 3,300 sq ft pilot-scale development facility sits alongside 2,700 sq ft of Phase 1 and 2 GMP clean rooms. The site has been successfully inspected by Health Canada, the US FDA, and the EMA, which reduces your regulatory uncertainty considerably.

Contact Eurofins CDMO directly to discuss how their capabilities align with your program's stage and requirements.